Target: MMP9
Conjugate: HRP
Product Type: Monoclonal
Clone Number: L51/82 (Formerly sold as S51-82)
Immunogen: Fusion protein amino acids 1-708 (full length) of rat MMP9
Swiss-Prot: P50282
Purification: Protein G Purified
Storage Buffer: 73.64mM Carbonate, 54.55mM Ethanolamine, 45.45mM Cyanoborohydride, 18.18mM Sodium Hydroxide and 0.23mM Citrate in dH2O
Concentration: 1 mg/ml
Specificity: Detecs ~92kDa and ~82kDa (pro and active forms).
Cellular Localization: Extracellular Matrix
Scientific Background: MMP9, otherwise known as matrix metalloproteinase 9, is involved in the breakdown of extracellular matrix in normal physiological processes such as embryonic development, reproduction and tissue remodeling, as well as in disease processes like arthritis and metastasis (1). Among the family members, MMP-2, MMP-3, MMP-7 and MMP-9 have been characterized as important factors for normal tissue remodeling during embryonic development, wound healing, tumor invasion, angiogenesis, carcinogenesis and apoptosis (2-4). MMP activity correlates with cancer development (2). One mechanism of MMP regulation is transcriptional (5). Once synthesized, MMP exists as a latent proenzyme. Maximum MMP activity requires proteolytic cleavage to generate active MMPs by releasing the inhibitory propeptide domain from the full length protein (5).
References: 1. Hirose Y., et al. (2008) Am J Hum Genet. 82(5): 1122-1129.2. Coussens L.M., et al. (2002) Science 295: 2387-2391. 3. Sternlicht M.D., et al. (1999) Cell 98: 137-146. 4. Vu T.H., et al. (1998) Cell 93: 411-422. 5. Nagase H., et al. (1990) Biochemistry 29: 5783-5789.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
